SEPN

Septerna Inc/$SEPN

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Septerna Inc

Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, GLP-1R, GIPR, and GCGR.

Ticker

$SEPN
Primary listing

Industry

Pharmaceuticals

Employees

75

ISIN

US81734D1046

Septerna Inc Metrics

BasicAdvanced
$467M
-
-$3.89
-
-

Bulls say / Bears say

Septerna's recent collaboration with Novo Nordisk, valued at up to $2.2 billion, to develop oral treatments for obesity and type 2 diabetes, positions the company favorably in the expanding metabolic disease market (reuters.com).
The company's strong financial position, with $420.8 million in cash and equivalents as of December 31, 2024, provides a solid foundation for ongoing research and development efforts (globenewswire.com).
Septerna's successful IPO in October 2024, which raised $331.2 million and saw shares rise nearly 31% on debut, reflects strong investor confidence in the company's prospects (reuters.com).
The discontinuation of the SEP-786 Phase 1 clinical trial due to elevated unconjugated bilirubin levels raises concerns about the viability of this lead candidate and potential delays in product development (globenewswire.com).
Despite a strong cash position, Septerna reported a net loss of $71.8 million for the full year ended December 31, 2024, highlighting ongoing financial challenges common in biotech firms (globenewswire.com).
The competitive landscape in the biotech sector, particularly in GPCR-targeted therapies, may pose challenges for Septerna in differentiating its products and achieving market penetration.
Data summarised monthly by Lightyear AI. Last updated on 9 Jun 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $SEPN

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs